Bridging Discovery and Manufacturing: Scalable Purification Strategies for GLP-1 Analogs

Matthew Crawford

The rapid commercialization of glucagon-like peptide-1 (GLP-1) analogs has reshaped the therapeutic and manufacturing landscape, driving innovation across peptide development platforms. However, the path from early discovery to commercial-scale manufacturing presents significant challenges—particularly in translating flexible, high-throughput purification methods into robust, validated production processes.
During discovery, purification workflows are optimized for speed and adaptability across diverse peptide libraries that vary in sequence, hydrophobicity, and charge. These systems often depend on broadly applicable chromatographic solvents and modifiers that facilitate rapid screening but limit scalability and reproducibility. At process scale, manufacturing operations must instead emphasize regulatory compliance, process robustness, and cost efficiency. Aligning these distinct priorities is a critical step toward achieving reliable, large-scale production of GLP-1 analogs and related peptide therapeutics.

This webinar, presented by Matthew Crawford, will explore the scientific and operational strategies required to bridge discovery-phase purification methods with cGMP manufacturing processes. Attendees will gain insight into how early communication between research and process development teams can streamline method transfer, reduce rework, and accelerate readiness for scale-up and commercialization.

Watch the full presentation here:

https://www.youtube.com/watch?v=onbMItpag-8